Posttransplant diabetes mellitus in cyclosporine-treated renal allograft patients: a case-control study.
The incidence and risk factors for the development of posttransplant diabetes mellitus (PTDM) was retrospectively evaluated in cyclosporine-treated renal transplant patients. An incidence of 9.4% was observed over a 10-year period. Weight and body mass index were risk factors identified in a case-controlled study. Age, race, family history of DM, and cyclosporine and prednisone doses were not associated with the development of PTDM. We concluded that the development of PTDM is mainly related to weight. All efforts must be taken to avoid this complication.
Copstein
L A
LA
Nephrology Post-Graduation Program, UFRGS Medical School and Division of Nephrology, Hospital de Clínicas de Porto Alegre, Porto Alegre RS, Brazil.
Zelmanovitz
T
T
Gonçalves
L F
LF
Manfro
R C
RC
D000328:Adult; D016022:Case-Control Studies; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008875:Middle Aged; D012189:Retrospective Studies; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016572:Cyclosporine